
Bio-Thera’s Anti VEGF Therapy for w-AMD Meets Phase III Endpoint, Prepares for Market Filing
— Reported by DengYueMed On June 24, 2024, Bio-Thera Solutions, Ltd. announced that its anti…

— Reported by DengYueMed On June 24, 2024, Bio-Thera Solutions, Ltd. announced that its anti…

Molecular Glues: Unique Mechanism Of Action Wide Market Prospects Earlier this year, AbbVie announced a…

Krazati (adagrasib) is a promising targeted therapy developed to treat certain cancers with a specific…

Introduction Amvuttra dosing (vutrisiran) is a new-generation RNA interference (RNAi) therapy used for the treatment…

Introduction Diagnosed with breast cancer? You’re not alone. Explore this blog to understand what breast…

Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive form of lung cancer, accounting for ~70% of…

Introduction Anaplastic Lymphoma Kinase (ALK) is a genetic mutation that can drive the development of…

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting…

Introduction “It was just some blood in my stool. I thought it was hemorrhoids. But…

🔍 What is Atopic Dermatitis? Atopic dermatitis (AD) is a chronic inflammatory skin condition affecting…